Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atypical haemolytic uraemic syndrome01.06.02.003; 20.01.03.027; 17.02.10.027; 07.11.01.0320.000028%Not Available
Biliary obstruction09.02.02.0050.000056%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000468%Not Available
Breast necrosis21.05.04.016--Not Available
Brown-Sequard syndrome17.10.01.025; 12.01.13.0090.000028%Not Available
Catarrh22.12.03.0020.000028%Not Available
Cerebral mass effect17.11.01.0190.000440%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000056%Not Available
Chordae tendinae rupture02.04.02.0400.000042%Not Available
Coagulation factor deficiency01.01.01.0140.000028%Not Available
Colorectal adenoma16.05.02.009; 07.20.01.0190.000070%Not Available
Decompensated hypothyroidism05.02.03.010; 14.11.01.0500.000028%Not Available
Drug-disease interaction08.06.03.0120.000028%Not Available
Epiphyseal disorder15.02.02.0030.000042%Not Available
Gallbladder rupture09.03.02.012; 12.01.17.0050.000056%Not Available
Gastroduodenal haemorrhage24.07.02.063; 07.12.01.0080.000028%Not Available
Gastrointestinal vascular malformation haemorrhagic24.07.02.064; 07.15.04.0100.000028%Not Available
Haematoma muscle24.07.01.091; 15.05.03.036; 12.01.07.0150.000468%Not Available
Haemoperitoneum24.07.02.065; 12.01.17.007; 07.07.02.0070.000575%Not Available
Haemorrhage foetal24.07.01.093; 18.03.02.0240.000028%Not Available
Haemorrhagic cholecystitis24.07.01.094; 09.03.01.0080.000098%Not Available
Intermenstrual bleeding21.01.01.015--Not Available
Lacrimal haemorrhage24.07.05.018; 06.07.02.0110.000028%Not Available
Left ventricular diastolic collapse02.04.02.0430.000028%Not Available
Left ventricular dilatation02.04.02.0440.000028%Not Available
Lung opacity22.12.01.0060.000028%Not Available
Medical device site haematoma24.07.01.100; 08.07.01.028; 12.02.21.0120.000028%Not Available
Medical device site thrombosis24.01.01.042; 12.02.21.025; 08.07.01.0410.000084%Not Available
Neonatal respiratory distress18.04.10.004; 22.11.02.0150.000028%Not Available
Neovascular age-related macular degeneration06.09.03.0330.000028%Not Available
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene